Global Tuberculosis Diagnostics Market Analysis, Growth, Trends & Forecast 2018-2023, With an Expected CAGR of 4.5% - ResearchAndMarkets.com
DUBLIN--(BUSINESS WIRE)--Aug 7, 2018--The “Global Tuberculosis Diagnostics Market - Segmented by Diagnostic Test Type, End User, and Geography - Growth, Trends, and Forecast (2018 - 2023)” report has been added to ResearchAndMarkets.com’s offering.
The global tuberculosis diagnostics market is expected to register a CAGR of nearly 4.5%, during the forecast period of 2018-2023.
According to the World Health Organization (WHO), about 10 million people are affected by tuberculosis, each year. Further, tuberculosis is the leading cause of death from a single infectious agent, ranking above HIV/AIDS. In addition, the WHO also states that the developing economies of Asia-Pacific, Africa, and Latin America account for the major burden related to tuberculosis, MDR TB, and TB associated with HIV, as of 2017. As per a 2017 report of the WHO, about 153,000 patients with MDR/rifampicin resistant (RR) TB were detected worldwide, in 2016.
The cost associated with tuberculosis diagnostics varies across laboratories and hospitals, globally. According to Unitaid, the use of GeneXpert MTB/RIF is primarily hampered owing to its high cost, particularly in the emerging markets. Further, China and India were among the countries that reflect higher costs of tests and increased expansion of the private sector. This is further linked with the unavailability of proper laboratory capacities.
Owing to the presence of a large, diversified patient population and high burden of tuberculosis, Asia-Pacific is expected to retain its market position, over the forecast period. Countries, such as India, China, Indonesia, and Afghanistan are among the top-priority countries for the control of communicable diseases, according to the WHO. China and India registered the highest number new cases of tuberculosis annually, followed by African and Latin American countries.
Companies MentionedAbbott Becton Dickinson and Company BioMrieux SA Cepheid F. Hoffmann-La Roche AG Hain Lifescience GmbH Hologic Corporation Qiagen Siemens Thermo Fisher Scientific Inc.
Key Topics Covered:
2. Research Methodology
3. Executive Summary
4. Key Inferences
5. Market Overview
6. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)
7. Market Segmentation
8. Competitive Landscape
9. Key Players
10. Future of the Market
For more information about this report visit https://www.researchandmarkets.com/research/vgxp43/global?w=4
View source version on businesswire.com:https://www.businesswire.com/news/home/20180807005356/en/
Laura Wood, Senior Manager
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics:Infectious Disease Testing
INDUSTRY KEYWORD: HEALTH INFECTIOUS DISEASES
SOURCE: Research and Markets
Copyright Business Wire 2018.
PUB: 08/07/2018 05:44 AM/DISC: 08/07/2018 05:44 AM